Experian (EXPGY)
(Delayed Data from OTC)
$42.52 USD
-0.02 (-0.05%)
Updated May 9, 2024 10:23 AM ET
3-Hold of 5 3
D Value A Growth D Momentum B VGM
Price, Consensus and EPS Surprise
EXPGY 42.52 -0.02(-0.05%)
Will EXPGY be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for EXPGY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EXPGY
Experian (EXPGY) Upgraded to Buy: Here's Why
Zacks Industry Outlook Highlights Experian, FactSet Research Systems and Intertek
EXPGY: What are Zacks experts saying now?
Zacks Private Portfolio Services
3 Stocks to Buy From the Booming Business Information Industry
PubMatic (PUBM) Extends Adverty Partnership, Boosts Prospects
PubMatic (PUBM) Expands in India With PhonePe Collaboration
Other News for EXPGY
New Experian Tool Empowers Financial Inclusion Through Open Banking Insights
Experian announces launch of Cashflow Attributes solution
UK earnings, trading statements calendar - next 7 days
Which Credit Bureau Stock Should You Buy for the Long-Term?
Access to Healthcare and Digital Tools Turning a Corner for the Better, According to Providers and Patients